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Abstract: PURPOSE: Early stage lung cancer is treated with stereotactic body radiation therapy (SBRT)
in patients who are unable or unwilling to undergo surgical resection. Some patients’ comorbidities are
so severe that they are unable to even undergo a biopsy. A clinical diagnosis without biopsy before
SBRT has been used, but there are limited data on its efficacy. METHODS AND MATERIALS: Data
on patients treated with SBRT for non-small cell lung cancer, with and without tissue confirmation,
were collected from multiple institutions across Europe, Canada, and the United States. Patients with
a minimum of 2 years of comprehensive follow up were selected for analysis. Treatment and patient
characteristics were compared. Overall survival (OS), disease-free survival (DFS), cause-specific survival
(CSS), and rates of local recurrence (LR), regional recurrence (RR), and distant metastasis (DM) were
calculated and analyzed. RESULTS: A total of 701 patients were identified, of which 67% had tissue
confirmation of their tumors. The 3- and 5-year outcomes for OS, CSS, and DFS were 83.8%, 93.1%,
69%, and 60.6%, 86.7%, 45.5%, respectively. The rates for LR, RR, and DM at 3 and 5 years were 6.4%,
9.3%, 14.3%, and 10.5%, 14.3%, 19.7%, respectively. There were no statistically significant differences in
survival outcomes or recurrences between the biopsy and no-biopsy cohorts. CONCLUSIONS: SBRT for
clinically diagnosed lung cancers is efficacious in appropriately selected patients, with similar outcomes as
those with a pathologic diagnosis. Thorough clinical and radiographic evaluations in a multidisciplinary
setting are critical to the management of these patients.
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Early stage lung cancer is treated with stereotactic body radiotherapy (SBRT) in patients unfit or 
unwilling to undergo surgical resection. Some patients’ comorbidities are so severe that they are 
unable to even undergo biopsy. Clinical diagnosis without biopsy before SBRT has been utilized, 
but there are limited data on its efficacy. 
Methods 
Data on patients treated with SBRT for non-small cell lung cancer (NSCLC), with and without 
tissue confirmation, were collected from multiple institutions across Europe, Canada, and the 
United States. Patients with a minimum of two years of comprehensive follow up were selected 
for analysis. Treatment and patient characteristics were compared. Overall survival (OS), 
disease-free survival (DFS), cause-specific survival (CSS), rates of local recurrence (LR), 
regional recurrence (RR), and distant metastasis (DM) were calculated and analyzed. 
Results 
Seven hundred one patients were identified, of which 67% had tissue confirmation of their 
tumors. OS, CSS, and DFS three and five-year outcomes were 83.8%, 93.1%, 69%, and 60.6%, 
86.7%, 45.5%, respectively. LR, RR, and DM rates at three and five-years were 6.4%, 9.3%, 
14.3%, and 10.5%, 14.3%, 19.7%, respectively. There were no statistically significant 
differences in survival outcomes or recurrences between the biopsy and no biopsy cohorts. 
Conclusions 
SBRT for clinically diagnosed lung cancers is efficacious in appropriately selected patients, with 
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similar outcomes as those with pathologic diagnosis. Thorough clinical and radiographic 
evaluation in a multidisciplinary setting is critical to the management of these patients. 
Introduction 
Lung cancer is the second most common non-cutaneous malignancy in the United States, 
with the highest mortality rate.1 The vast majority of cases are non-small cell lung cancer 
(NSCLC), with 60% - 70% of patients presenting with locally advanced or metastatic disease, 
and only 20 – 30% as early-stage.2,3 Even in early-stage disease, untreated NSCLC has a poor 
prognosis, with a median survival time of  just over one year.4–6 The standard of care for early-
stage disease is lobectomy and mediastinal lymph node dissection.7  However, a high incidence 
of comorbidities often results in patients being unable to undergo curative resection. 
Stereotactic body radiotherapy (SBRT) utilizes highly conformal, high dose per fraction 
radiation therapy, often used in early-stage NSCLC patients, with trials both domestically and 
abroad demonstrating excellent local control rates.8–11 This is a highly favorable treatment option 
for medically inoperable patients, which has been demonstrated to be safe in elderly patients and 
those with poor pulmonary function.12–14 Unfortunately, some patients have significant 
comorbidities precluding tumor biopsy for tissue confirmation, or they decline to undergo 
biopsy.15  
Recognizing this limitation, the utilization of SBRT in clinically diagnosed patients (i.e., 
without biopsy) has been growing, most pronounced in Europe, with the largest study comparing 
patient outcomes with or without tissue confirmation reported from the Netherlands and showing 
similar treatment results between two cohorts.16 In the US as well, there has been an increase in 
SBRT utilization for clinically diagnosed lung cancer in elderly and medically inoperable 
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patients.17,18 Although SBRT is generally considered safe, it does carry with it a certain risk of 
side effects and toxicity, and must be delivered judiciously. There is also concern that improper 
patient selection may result in overtreatment of incidentally detected, slow growing lesions.19 
Indeed, there have been efforts to improve patient selection to minimize unnecessary therapy.16,20 
While the Dutch analysis demonstrated equivalent outcomes, the patients were derived from a 
homogenous population at a single institution, and the generalizability of the results remains 
uncertain. 
Our group has previously published on the efficacy of image-guided SBRT for early-
stage NSCLC with high rates of local control and acceptable rates of toxicity.11 In this report, we 
studied the outcomes of SBRT for clinically diagnosed NSCLC lesions with and without 
pathologic confirmation. 
Materials and Methods 
Patients and Work-Up 
Patients treated between 2004 – 2014 across five international institutions (Xxxxxxx 
Xxxxxxxx Xxxxxxxx, Xxxxx Xxx, Michigan; Xxxxxxxxxx Xxxxxxxx Xxxxxxxx, Xxxxxxxx, 
Germany; Xxxxxxxxxxx Xxxxxx Xxxxxxxxx, Xxxxxxxxx, Netherlands; Xxxxxxx Xxxxxxxx 
Xxxxxxxx, Xxxxxxx, Xxxxxxx, Canada; and Xxxxxx Xxxxxxxxx Xxxxxxxxxx Xxxxxxxx, 
Xxxxxxxxxxxx, Pennsylvania) were included. Patient workup included at a minimum: history, 
physical examination, computed tomography (CT) scans of the chest and upper abdomen, 
including liver and adrenals, and serum chemistries. 18-fluorodeoxyglucose positron emission 
tomography (18FDG-PET) scans and pulmonary function tests (PFTs), and any additional 
workup was performed at the discretion of the respective institutions, including bone scans and 
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brain imaging. Tissue confirmation was obtained based on multiple factors including patient risk, 
biopsy difficulty, patient willingness, etc. Method of primary and lymph node biopsy, and 
diagnosis in the absence of tissue biopsy, was at the discretion of each institution’s oncology and 
multidisciplinary teams. Exclusion criteria included metastatic disease, greater than ten fractions 
radiation therapy, and non-NSCLC histology. 
Treatment and Follow-Up 
Technical details of SBRT delivery were described in a previous publication.11 Briefly, 
all patients underwent CT simulation with 3D planning, with 4D scans to account for tumor 
motion required starting in 2006. Immobilization techniques differed between institutions 
including stereotactic body frame, supine position without custom immobilization, and other 
immobilization techniques. All institutions delineated the gross tumor volume (GTV) using CT 
lung windowing with mediastinal windowing as needed for lesions abutting a pleural surface. 
The internal target volume (ITV) was based on a 4D scan.  Any clinical target volume (CTV) 
expansion was done at the discretion of each institution’s policies, and a minimum planning 
target volume (PTV) of 0.5cm was employed. Treatment was typically delivered with 6 MV 
photons using between 5-12 beams with segments, including both coplanar and non-coplanar 
arrangements. Heterogeneity correction was used for dose calculation and analysis, with a 
volumetric prescription to the PTV edge. Prescription dose and fractionation was at each 
respective institution’s discretion.  Normal tissue constraints were based on institution policy or 
Radiation Therapy Oncology Group (RTOG) guidelines. All patients on treatment underwent 
daily cone-beam computed tomography (CBCT) for imaging verification.   
All patients underwent routine follow up with a minimum of thoracic CT scans obtained 
every three to six months during the first two years, with the incorporation of 18FDG-PET at the 
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discretion of the institution. Evaluation of recurrence was based on serial CT chest, 18FDG-PET, 
and biopsy when feasible. The follow up period was defined from end of SBRT until last follow 
up or death. Local recurrence was defined as occurring within the treatment volume; regional 
recurrence within regional lymph nodes, and distant recurrence elsewhere. Toxicity evaluation 
was based on National Cancer Institute Common Toxicity Criteria Version 3. 
Statistical Analysis 
Each institution received local IRB approval. The details of patient characteristics, 
treatment specifics, clinical outcomes, and toxicity were verified before anonmyziation and 
analysis. Only those patients with a minimum of two years of follow up were used for the 
analysis of overall survival (OS), cause-specific survival (CSS), disease-free survival (DFS), 
local recurrence (LR), regional recurrence (RR), and distant metastases (DM). This was done to 
ensure robust outcome data and to highlight detectable signals in recurrence patterns, which has 
particular importance when analyzing biopsied vs. not-biopsied tumors. Student’s unpaired t-test 
and Pearson’s chi-squared exact test were used to compare continuous and categorical variables 
among groups, respectively, to evaluate potential discrepancies among patient subgroups 
concerning patient, treatment, or tumor-related factors. Analyses of DFS, CSS, and OS were 
calculated and compared using the Kaplan–Meier method. Estimates of LR, RR, and DM were 
calculated using the competing risk method. Doses were standardized for analysis based on 
biological equivalent doses (BEDGy10). Univariate and multivariate analyses were performed 
using the Cox Regression model. Findings were considered statistically significant if the p-value 
was <0.05 or if 95% confidence interval (CI) did not encompass one, and all statistical tests were 
two-sided. Additional analyses looking at outcomes by size, synchronous, and metachronous 
lesions were done to better characterize disease characteristics. Statistical analyses were 
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Of the entire cohort, 701 patients with 752 tumors (58.4%) had follow up of at least two 
years, with a median follow up of 3.7 years (range 2.0 – 11.4). Median patient age was 74 years 
(range 42.0 – 93.5) and 87.9% were considered inoperable with a Karnofsky Performance Status 
of 80.  PFTs were obtained in 88% of patients, with median forced expiratory volume in one 
second (FEV1) of 1.63L (56.9% predicted), and median diffusing capacity for carbon monoxide 
(DLCO) of 9.73ml/min/mmHg (51.7% predicted). Typical tumors had a maximum diameter of 
2.0cm (range 0.5 – 9.6), and were peripheral as per the RTOG 0236 definition (88.4%).8 18FDG-
PET staging was completed in 94.8% of patients.  A detailed list of patient and lesion 
characteristics are available in Table 1. 
T-test comparison of patient factors between the “biopsy” and “no biopsy” groups 
revealed statistically significant differences and are listed in Table 2. In general, higher mean 
values were present in the biopsy group for age, baseline 18FDG-PET maximum standardized 
uptake value (SUVmax), tumor size, lymph node evaluation, and number of fractions/treatment 
days (p<0.05). Only number of peripheral lesions was higher in the no biopsy cohort (86.3% vs 
93.1%, p=0.01).  
Treatment Details 
4D CT simulation was performed in 86.3% of patients, and CBCT image guidance before 
each fraction was utilized in 100% of SBRT deliveries. Median prescription dose to the PTV was 
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54.0Gy (range 26 – 60) in 3 fractions (range 1 – 10), with median BEDGy10 to the PTV of 
144Gy (range 60 – 180).  Median lung V20 (volume of lung not including GTV receiving 20Gy 
or greater) was 6.0% (range 0 – 40).  Analysis of dosimetric variables between the biopsy and no 
biopsy groups (Table 2) revealed higher prescription dose, Dmean (mean dose delivered), Dmax 
(maximal dose delivered) and Dmin (minimal dose delivered) to the GTV and PTV for the no 
biopsy group (p<0.01). There was no difference in lung V20Gy (volume of lung receiving 20Gy 
or greater), but higher lung Dmean (p<0.01) in the biopsy group. 
Outcomes and Analysis 
The 3- and 5-year LR, RR, and DM rates for all patients with at least two years of follow 
up were 6.4%, 9.3%, 14.3%, and 10.5%, 14.3%, 19.7%, respectively. OS, CSS, and DFS at 3- 
and 5-years for all patients with at least two years of follow up were 83.8%, 93.1%, 69%, and 
60.6%, 86.7%, 45.5%, respectively. There were no significant differences in recurrence (Figures 
1a, 1b, 1c) or survival rates (Figures 2a, 2b, 2c) between the biopsy vs. no biopsy groups (Table 
3). Consistently demonstrated between both cohorts were high mortality rates as a competing 
risk event to local, regional, and distant recurrence (Figures 1a, 1b, 1c). Univariate analysis 
evaluating risk factors for LR based on tumor and treatment factors did not reveal any significant 
factors (p>0.05), although lymph node tissue evaluation with an HR of 2.28 (95% CI 0.91 – 
5.70, p=0.08), and administration of chemotherapy with an HR of 2.68 (95% CI 0.97 – 7.38, 
p=0.06) were trending for significance (Table 4). Analysis of OS and CSS including patients 
with less than 2 years of follow up did not reveal significant differences (p>0.05) between the 
biopsy and no biopsy cohorts suggesting no selection bias by our selection criteria 
(Supplementary 1). Analysis of LR, RR, DM based on size (≤2cm vs. >2cm) revealed nearly 
significant higher rates of local recurrence (p=0.08), but no statistically significant differences in 
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RR and DM (p>0.1). Patients with synchronous or metachronous tumors did not have 
significantly higher rates of RR (p>0.05), but both had significantly higher rates of DM 
compared to those with a single tumor (p<0.01). Figures and analyses are available in the 
supplementary (Supplementary 2, 3, 4). 
Discussion 
Our study demonstrates that appropriately selected patients with clinically diagnosed, 
early-stage NSCLC who are unable or unwilling to undergo tissue confirmation derive similar 
outcomes after SBRT as patients with biopsy-confirmed tumors. This benefit was not limited to 
local control and OS, and also included similar rates of RR, DM, and CSS. These other endpoints 
are particularly notable as they reinforce the hypothesis that patient selection for SBRT without 
biopsy was appropriate. Clinical differences between the cohorts were minimal. Dosimetric 
differences were notable for higher BEDGy10 in the no biopsy cohort (Table 2). However, 
median prescription and Dmean BEDGy10 in both cohorts were well above 100 BEDGy10 which 
is considered the necessary threshold to obtain the high rates of local control quoted in modern 
trials and series.10,11 
We focused our analysis on patients with a minimum of two years of follow up. This was 
done to confirm comprehensive follow up length for analysis, and to evaluate patients who 
would most benefit from treatment as competing comorbidities/risk factors for death are well 
established in this patient group. In addition, longer follow up is associated with greater rates of 
regional and distant failure,21 and would potentially highlight discordance between the cohorts if 
benign lesions were treated in the no biopsy cohort. Despite this, our rates of LR, RR, and DM 
were similar to those reported by Verstegen et al. from the Netherlands.16 While our rates of OS 
were higher than those reported in their report (3yr-OS 83.8% vs. 55.4%), this may be a result of 
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our minimum two-year follow-up requirement rather than unique treatment outcomes. 
Comparison to our unselected cohort suggests similar survival (Supplementary 1), and there was 
no difference between the biopsy and no biopsy groups. When comparing our results to 
prospective trials with long term follow up, our 5 year local, regional, and distant recurrence 
rates are similar to those reported by Timmerman et al. and Sun B et al. (~8%, ~11%, 11-
24%).21,22  
Rates of empiric SBRT therapy have steadily increased nationally in the United States, 
estimated to be greater than 5% in 2011, with rates likely to have increased since then.18 This 
greater willingness to use the modality by radiation oncologists is likely a manifestation of 
increased experience with SBRT, overall low levels of toxicity observed, as well as higher rates 
of referrals once general awareness increased among other physicians. While tissue biopsy 
confirmation is always preferable, this may not be feasible in in those who refuse biopsy, have 
undergone non-diagnostic biopsy, or who may carry prohibitive risk with biopsy. Indeed, official 
American Society of Radiation Oncology (ASTRO) guidelines for SBRT in patients with early 
NSCLC recognize the appropriateness of empiric treatment in this patient population, after 
exhausting efforts to obtain biopsy, with a recommendation strength of “strong” and a 100% 
committee consensus.23  
Treatment of patients with clinically diagnosed early-stage lung cancer requires careful 
staging and risk stratification. There are multiple guidelines by various organizations and 
societies to help guide evaluation and management of pulmonary nodules, including those from 
the Fleischner Society, American College of Chest Physicians (ACCP), International Association 
for the Study of Lung Cancer (IASCL), American College of Radiology (ACR) Lung-RADS 
system, and British Thoracic Society.24–27 Consistent across these guidelines is an emphasis on 
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clinical and radiographic characteristics considered in a multidisciplinary setting. Incorporation 
of PET scans into risk stratification models of pulmonary nodules has been shown to increase 
sensitivity and receiver operating characteristic (ROC) curves.28 Proper risk stratification is 
paramount, with ACCP guidelines recommending a pre-test probability cutoff of >65% to 
consider surgical diagnosis, while other models have suggested higher cutoffs as high as 85% for 
empiric PET scan-directed SBRT.20,25,29 A recent publication by the Lung Cancer Collaborative 
Group suggested guidelines in the empiric use of SBRT for NSCLC including workup and 
treatment considerations, with specific recommendations for suspected tumors >3cm vs. ≤3cm 
vs. ground glass nodules.30 The management of patients unfit or unwilling to undergo biopsy for 
suspected NSCLC will become only more sophisticated in the future with the refinement of 
circulating tumor cells and DNA, known as “liquid biopsies,” in risk stratification.31,32 
Probability calculators have also been developed to provide more quantitative measures 
for physicians. These calculators include Mayo Clinic, Veterans Association, Pan-Canadian 
Early Detection of Lung Cancer Study (PanCan), and Vrije Universiteit (VU) models.33–36 
Similar to society guidelines, these calculators take into consideration patient demographics and 
radiographic characteristics, with the VU model also incorporating FDG avidity on PET scans. 
Validation studies of those calculators demonstrated good accuracy in the Mayo and PanCan 
models, with the highest accuracy seen with 18FDG-PET scan information in the VU model.37 In 
general, these models describe older patients with large, solid, spiculated, PET-avid lesions in 
the upper lobe in the setting of prior cancer and tobacco use being at the highest risk of 
malignancy. A limitation of these tools is their inability to take into consideration confounding in 
areas and populations with high rates of benign radiographic findings.38 Examples would be 
areas and populations with high rates of tuberculosis, histoplasmosis, blastomycosis, 
11 
 
coccidioidomycosis, etc. In a meta-analysis by Deppen et al, 70 studies evaluating 8,511 nodules 
were analyzed in the PET staging era.39 When analyzing studies in areas with endemic infectious 
lung disease, specificity was found to be 16% lower. This may pose a particular issue in parts of 
the United States where granulomatous fungal infections occur commonly. Ultimately, this 
reinforces the need for careful risk stratification based on clinical and radiographic information 
in a multidisciplinary manner by physicians familiar with the respective patient population. 
Prior reports on the subject have consistently demonstrated largely equivalent outcomes 
between biopsy and no biopsy groups. The largest series was the Dutch report with nearly 600 
patients with over 30 months median follow up, 65% treated empirically, with no differences in 
OS or disease control.16 Single institution experiences in the United States have also been 
reported, with largely consistent results. Wegner et al. published their experience at Allegheny 
General Hospital in Pittsburgh, PA with 196 patients, 51% without biopsy, with a median follow 
up of 17 months, with no difference in OS, LR, RR, or DM.40 Haidar et al. at the University of 
California San Diego reported SBRT outcomes of 55 patients, 41% without biopsy.41 With a 
median follow up of 25.8 months, they reported no significant differences in OS. While these 
reports together are reassuring, they are restricted in their generalizability due to their largely 
single institution nature, homogenous patient populations or low patient number with limited 
follow up. This concern was highlighted in the meta-analysis by IJsseldijk et al. which compared 
43 studies with over 11,000 patients with clinically or pathologically diagnosed early-stage 
NSCLC treated with SBRT. Comparative and pooled analysis generally revealed lower OS, CSS, 
and DFS in the biopsy diagnosed group.42 The studies included in their analysis did not all utilize 




Our study has several strengths worthy of discussion. Patients in our study were nearly all 
18FDG-PET staged, increasing diagnostic probability using modern staging methods. All 
patients were treated with 3D, volumetrically prescribed, image-guided radiotherapy (IGRT) via 
CBCT. Analyses of all dose-volume relationships and clinical outcomes were based on 
heterogeneity-corrected dose. Seven hundred fifty lesions in 701 patients with a median follow-
up of nearly four years were reported, greater than those listed in the Dutch study and the largest 
data set available. Our results represent the experiences of multiple, international institutions 
across Europe and North America, increasing the potential for generalizability.  
Limitations of our study should also be taken into consideration when interpreting our 
results. Around 44% of reported lesions were treated in the Netherlands, representing a 
significant proportion of patients. Patient risk stratification and decision to pursue treatment was 
done at the discretion of each respective institution’s oncology and multidisciplinary teams, with 
no uniform probability metric or cutoff. There was a wide range of SBRT techniques utilized in 
our study that is reflective of the efforts of early adopters of SBRT due to a proportion of our 
patients that were treated before the publication of RTOG 0236 and standardization of 
techniques.8 This should not impact the overall efficacy of treatment and is present in both 
cohorts. We were not able to evaluate if there were ground glass lesions treated in the no biopsy 
cohort, and the lack of tissue diagnosis may have allowed for treatment of very early stage small 
cell lung cancer and/or treatment of more indolent forms of adenocarcinoma which may 
influence urgency of treatment.43–45 However, time from 18FDG-PET to treatment (Table 2) was 
not significantly different between our cohorts. We do not have data on rates of subsequent 
malignancies after treatment which have been noted to be up to 10% in the literature, and may 
confound the no biopsy cohort.46 PET/CT staging should have minimized the misdiagnosis of 
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head and neck primaries that presented with pulmonary lesions. We did not have explicit 
information on T3/4 lesions based on separate lung nodules which might have had different rates 
of RR and DM. We did report on the rate of synchronous and metachronous rates in each cohort, 
and analysis did not reveal significant difference (Table 2). Continued smoking after diagnosis 
and treatment of lung cancer has been noted to affect treatment outcomes and was not available 
in our data set.47 Toxicity or quality of life data was not recorded although prior studies in the 
elderly and patients with significant co-morbidities have been previously reported.12,14 
Conclusion 
SBRT for clinically diagnosed early-stage NSCLC provides efficacious and equivalent 
outcomes in appropriately selected patients when compared to those with a pathologic diagnosis. 
Patients being considered for empiric SBRT should undergo comprehensive risk stratification 
incorporating clinical and radiographic information, in a multidisciplinary setting. 
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Table 1. Patient and Lesion Characteristics 
FEV1 – forced expiratory volume in one second, DLCO – diffusing capacity for carbon 
monoxide, BEDGy10 – biological equivalent dose using and alpha/beta of 10Gy, 4DCT – 4 
dimensional computed tomography, CBCT – cone beam computed tomography, Lung V20Gy – 
volume of lung receiving 20Gy or greater. 
 
Table 2. Comparison of Cohort Variables 
FEV1 – forced expiratory volume in one second, DLCO – diffusing capacity for carbon 
monoxide, PET – positron emission tomography, SUVmax – maximum standardized uptake 
value, GTV – gross tumor volume, PTV – planning target volume, Dmean – mean target dose, 
Dmax – maximal target dose, Dmin – minimum target dose, Lung V20Gy – volume of lung 
receiving 20Gy or greater. 
 




Table 4. Univariate and Multivariate Analysis of Local Recurrence 
SUVmax – maximum standardized uptake value, PET – positron emission tomography, RT – 
radiotherapy, GTV – gross tumor volume, PTV – planning target volume, BEDGy10 – biological 
equivalent dose using and alpha/beta of 10Gy. 
 
Figure 1. Control Rates and Competing Risk of Death 
Comparison of local recurrences (1a), regional recurrences (1b), and distant metastases (1c) for 
patients with and without biopsy proven disease. Mortality rates shown to demonstrate 
competing risk. All p-values >0.1. 
 
Figure 2. Survival Data Comparisons 
Comparison of overall survival (2a), disease free survival (2b), and cause specific survival (2c) 
for patients with and without biopsy proven disease. All p-values >0.1. 
 
Table 1. Patient and Lesion Characteristics 
Characteristics  Values 
Median Age   74.2 (42 - 93.5) 
Sex     
Male   379 (50.4%) 
Female   373 (49.6%) 
Karnofsky Performance Status   80 (40 - 100) 
Prior Lung Cancer  80 (10.6%) 
Pulmonary Function Test   88%  
FEV1 Liters  (% predicted)   1.63 (56.9%) 
DLCO ml/min/mm (% predicted)   9.73 (51.7%) 
PET Staging     
Yes   713 (94.8%) 
No   39 (5.2%) 
Biopsy     
Yes   504 (67%) 
No   248 (33%) 
Mediastinal Evaluation     
Yes   48 (6.4%) 
No   704 (93.6%) 
Location (RTOG 0236)     
Central   86 (11.4%) 
Peripheral   665 (88.4%) 
Unknown   1 (0.2%) 
Histology (if biopsied)     
Adenocarcinoma   48.5% 
Squamous   30.6% 
Other   20.9% 
Treatment Parameters     
Dose (Gy)   54.0 (26 - 60) 
Fractions   3 (1 - 10) 
Median BEDGy10   144 (60 – 180) 
4DCT   86.3% 
CBCT   100% 
Median Lung V20Gy   6.0% 
Adjuvant Chemotherapy   2.7% 
Follow Up (years)   3.7 (2 - 11.4) 
Lesions by Institution     
William Beaumont Health   142 (18.9%) 
Thomas Jefferson University 
Hospital 
  44 (5.9%) 
Netherlands Cancer Institute   340 (45.2%) 
Princess Margaret Hospital   189 (25.1%) 
University Hospital Würzburg   37 (4.9%) 
FEV1 – forced expiratory volume in one second, DLCO – diffusing capacity for carbon 
monoxide, BEDGy10 – biological equivalent dose using and alpha/beta of 10Gy, 4DCT – 4 
dimensional computed tomography, CBCT – cone beam computed tomography, Lung V20Gy – 
volume of lung receiving 20Gy or greater. 
 









Age 74.1 72.2 0.01 
Treatment Duration (days) 7.9 7.3 <0.01 
Follow-Up (years) 4.11 3.9 0.1 
FEV1 (% predicted) 57.2 56.3 0.7 
DLCO (% predicted) 51.3 52.6 0.6 
Days from PET to Treatment 48.7 49.0 0.92 
Staging PET (%) 94.2 96 0.38 
Baseline SUVmax 7.1 5.9 0.02 
Peripheral location (%) 86.3 93.1 <0.01 
Mediastinal Evaluation (%) 4.8 0.8 <0.01 
Prior Lung Cancer (%) 9.1 13.7 0.22 
Synchronous Lesions (%) 9.5 13.3 0.13 
Metachronous Tumor (%) 11.9 13.7 0.48 
Max Dimension (cm) 2.4 2.0 <0.01 
Median Prescription BEDGy10 132 151 <0.01 
Fractions 3.9 3.4 <0.01 
GTV Dmean (BEDGy10) 187.7 220.2 <0.01 
GTV Dmax (BEDGy10) 196.4 220.5 <0.01 
GTV Dmin (BEDGy10) 150.5 169.6 <0.01 
PTV Dmean (BEDGy10) 167.7 191.5 <0.01 
PTV Dmax (BEDGy10) 190.8 212.1 <0.01 
PTV Dmin (BEDGy10) 98.8 108.4 <0.01 
Lungs V20Gy (%) 6.1 5.8 0.47 
Lungs Dmean (Gy) 3.5 1.5 <0.01 
Adjuvant Chemotherapy (%) 3.4 1.2 0.1 
 
FEV1 – forced expiratory volume in one second, DLCO – diffusing capacity for carbon 
monoxide, PET – positron emission tomography, SUVmax – maximum standardized uptake 
value, GTV – gross tumor volume, PTV – planning target volume, Dmean – mean target dose, 
Dmax – maximal target dose, Dmin – minimum target dose, Lung V20Gy – volume of lung 
receiving 20Gy or greater. 
Table 3. Recurrences and Survival Outcomes by Year 
Year Biopsy No Biopsy p-value 
% Local 
Recurrence 
1-Yr 0.6 1.6 
0.10 
2-Yr 4.6 3.2 
3-Yr 7.5 4.2 
4-Yr 9.9 5.8 
5-Yr 12.1 6.8 
% Regional 
Recurrence 
1-Yr 3.0 4.0 
0.99 
2-Yr 7.0 7.1 
3-Yr 9.3 9.1 
4-Yr 11.4 10.9 
5-Yr 14.0 15.1 
% Distant 
Metastases 
1-Yr 3.6 5.8 
0.38 
2-Yr 9.7 12.5 
3-Yr 13.6 16.7 
4-Yr 16.5 19.8 




1-Yr 100 100 
0.43 
2-Yr 100 100 
3-Yr 92.9 93.6 
4-Yr 90.5 90.2 
5-Yr 86.6 87.0 
% Disease 
Free Survival 
1-Yr 93.7 91.6 
0.64 
2-Yr 83.2 83.0 
3-Yr 69.7 67.7 
4-Yr 58.6 56.0 
5-Yr 46.5 43.9 
% Overall 
Survival 
1-Yr 100 100 
0.24 
2-Yr 100 100 
3-Yr 83.8 83.6 
4-Yr 73.8 70.0 












Hazard Ratio  
(95% CI) 
Max Tumor Dimension 0.69 
Baseline SUVmax 0.23 0.45 
Histology (for biopsy group) 0.31 0.28 
PET Staging (yes vs no) 0.43 
Operable (yes vs no) 0.94 
RT Dose (continuous) 0.35 
Central vs. Peripheral (RTOG 0236) 0.23 
Mediastinal Evaluation (yes vs no) 0.08 2.28 (0.91-5.70) 0.08 2.03 (0.91-4.55) 
Biopsy Done (yes vs no) 0.11 0.26 
Gender (female vs male) 0.63 
Chemotherapy Received (yes vs no) 0.06 2.68 (0.97-7.38) 0.12 
GTV Mean BEDGy10 0.35 0.24 
PTV Mean BEDGy10 0.52 
Previous Tumor (yes vs no) 0.59 
 
SUVmax – maximum standardized uptake value, PET – positron emission tomography, RT – 
radiotherapy, GTV – gross tumor volume, PTV – planning target volume, BEDGy10 – biological 
equivalent dose using and alpha/beta of 10Gy. 
 






